Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mibampator
- Development stage
- Phase 2
- Lead developer
- Eli Lilly
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Mibampator is a small molecule drug that acts as a positive allosteric modulator (PAM) of the AMPA receptor, an ionotropic glutamate receptor subtype. It was developed by Eli Lilly for the treatment of agitation and aggression in Alzheimer's disease. Mibampator belongs to the biarylpropylsulfonamide group of AMPAR PAMs and is considered a "high-impact" potentiator, capable of robustly increasing AMPAR signaling. In preclinical studies, high-impact AMPAR potentiators like mibampator enhanced cognition and memory at low doses but caused motor coordination disruptions, convulsions, and neurotoxicity at higher doses. Clinical trials in Alzheimer's disease showed no significant cognitive improvement but some benefit on neuropsychiatric measures; development was discontinued after phase II due to lack of efficacy and toxicity concerns[1][3][5].
- Other names
- mibampator
02
Targets
AMPAR (AMPA receptor)
Beyond the preview
Go deeper on mibampator.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mibampator.